Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.51 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.48 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP4 | P49662 | 1/20 | 0.47 |
| ▸ | CASP5 | P51878 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19928672 | 0.86 | CASP1 (0.40) | HRH4PRKD1PRKD2CASP1CASP4 | |
| SCHEMBL16809209 | 0.83 | NUDT1 (0.50) | HRH4CASP1CASP4CASP5ADRB1 | |
| SCHEMBL1775187 | 0.81 | HRH4 (0.67) | HRH4PRKD1PRKD2CASP1CASP4 | |
| SCHEMBL14702329 | 0.77 | CASP1 (0.47) | HRH4CASP1CASP4CASP5ADRB1 | |
| SCHEMBL19928686 | 0.77 | SRC (0.56) | HRH4FLT3ABL1SRC | |
| SCHEMBL14538233 | 0.76 | CASP1 (0.53) | HRH4CASP1CASP4CASP5ADRB1 | |
| SCHEMBL30376883 | 0.76 | CASP1 (0.53) | HRH4CASP1CASP4CASP5ADRB1 | |
| SCHEMBL25493012 | 0.75 | HTR3E (0.54) | HRH4PRKD1PRKD2CASP1CASP4 | |
| SCHEMBL14538237 | 0.74 | CASP1 (0.56) | HRH4CASP1CASP4CASP5ADRB1 | |
| SCHEMBL20905447 | 0.73 | KMT2A (0.51) | HRH4CASP1CASP4CASP5ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | HRH4 3627/4885PRKD1 886/4885PRKD2 1694/4885 |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | HRH4 3018/4885PRKD1 566/4885PRKD2 1332/4885 |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | HRH4 3018/4885PRKD1 566/4885PRKD2 1332/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | HRH4 3627/4885PRKD1 886/4885PRKD2 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.